Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AstraZeneca Transfers 5 Anesthetic Brands to Aspen in Japan under Global Deal
The Japan unit of AstraZeneca will transfer the marketing authorization and commercialization rights for five anesthetic brands (34 products) to Aspen Japan as of July 1 as part of their global deal announced in June last year, the two sides…
To read the full story
Related Article
- AZ to Divest 4 Off-Patent Drugs to Taiyo Pharma
April 30, 2020
- AstraZeneca Completes Transfer of Migraine Drug Zomig to Sawai
June 21, 2018
- AZ to Transfer Migraine Med Zomig to Sawai Mid-Next Year
October 6, 2017
- Aspen Japan to Take Over 4 Brands from Kyowa Kirin
July 4, 2017
- Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…